Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis

Published:2022-07-08 Issue:10 Volume:52 Page:824-832
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Tahata Yuki¹,Sakamori Ryotaro¹^ORCID,Yamada Ryoko¹,Kodama Takahiro¹^ORCID,Hikita Hayato¹^ORCID,Nozaki Yasutoshi²,Oshita Masahide³,Hiramatsu Naoki⁴,Miyazaki Masanori⁵,Mita Eiji⁶,Yamamoto Keiji⁷,Ohkawa Kazuyoshi⁸^ORCID,Kaneko Akira⁹,Ito Toshifumi¹⁰,Doi Yoshinori¹¹,Yakushijin Takayuki¹²,Hijioka Taizo¹³,Fukui Hiroyuki¹⁴,Imanaka Kazuho¹⁵,Yoshida Yuichi¹⁶,Yamada Yukinori¹⁷,Tatsumi Tomohide¹,Takehara Tetsuo¹^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Suita Japan

2. Kansai Rosai Hospital Amagasaki Japan

3. Ikeda Municipal Hospital Ikeda Japan

4. Osaka Rosai Hospital Sakai Japan

5. Osaka Police Hospital Osaka Japan

6. National Hospital Organization Osaka Medical Center Osaka Japan

7. National Hospital Organization Minami Wakayama Medical Center Tanabe Japan

8. Osaka International Cancer Institute Osaka Japan

9. Minoh City Hospital Minoh Japan

10. Japan Community Healthcare Organization Osaka Hospital Osaka Japan

11. Otemae Hospital Osaka Japan

12. Osaka General Medical Center Osaka Japan

13. National Hospital Organization Osaka Minami Medical Center Kawachinagano Japan

14. Yao Municipal Hospital Yao Japan

15. Itami City Hospital Itami Japan

16. Suita Municipal Hospital Suita Japan

17. Kaizuka City Hospital Kaizuka Japan

Funder

Japan Society for the Promotion of Science

Gilead Sciences

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13806

Reference34 articles.

1. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

2. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

3. Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C

4. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral

5. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surveillance and management of hepatocellular carcinoma after treatment of hepatitis C with direct-acting antiviral drugs;Annals of Hepatology;2024-09

2. High serum gamma‐glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma;Hepatology Research;2024-07-29

3. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response;Scientific Reports;2024-05-13

4. Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study;JGH Open;2024-04

5. Hepatocellular Carcinoma in the Era of Direct Antiviral Agents Against Hepatitis C Virus;Current Hepatology Reports;2024-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3